lidocaine patches

PreclinicalSmall molecule

RRenJi Hospital

lidocaine patches is one of 4 small molecule programs targeting Intravenous Lidocaine. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intravenous LidocaineUnknown status

Intravenous LidocainePreclinical

Unknown status

Competition

Competitive Landscape

3 competitors in Intravenous Lidocaine

#DrugCompanyPhaseTrials

Xylocaine

MMEDRx USA, Inc.

Approved

50 2

Xylocaine

MMEDRx USA, Inc.

Approved

7 3

Naropin

FFresenius Kabi USA, LLC

Phase 3

2 4

lidocaine patches

RRenJi Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intravenous1 trial

Lidocaine Patches for Attenuating the Pain of Venipuncture Intravenous Cannulation

Unknown status·RRenJi Hospital·Phase 2/3·NCT02061475·240 enrolled

Intravenous Lidocaine1 trial

Lidocaine Patch Versus Intravenous Lidocaine in Pain Relief After Laparoscopy

Unknown status·—·N/A·NCT04506034·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for lidocaine patches. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — lidocaine patches compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for lidocaine patches. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RenJi Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRenJi Hospital

lidocaine patches

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intravenous1 trial

Intravenous Lidocaine1 trial

References

Drug Info

Quick Facts

Related News